Terumo India expands interventional cardiology portfolio with the launch of FineCross™ M3

New Delhi: Terumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, has announced the launch of the FineCross™ M3 Coronary Micro-Guide Catheter in India.

This latest-generation catheter sets a new benchmark for percutaneous coronary intervention (PCI) by offering cardiologists superior crossing ability, enhanced guidewire support, and greater navigability in complex lesions that often hinder procedural success.

As coronary artery disease (CAD) continues to be the leading cause of death in India, with an increasing number of patients presenting complex lesions, the need for advanced interventional tools has become more critical than ever. Addressing this challenge, the FineCross™ M3 enables cardiologists to perform procedures that are more efficient, predictable, and safer, thereby improving both clinical outcomes and physician confidence.

Commenting on the launch, Shishir Agarwal, President and Managing Director, Terumo India, said, “Innovation at Terumo India is always guided by our mission to empower physicians in delivering the best possible care to patients. With the introduction of FineCross™ M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects not only our commitment to strengthening cardiovascular care in the country but also our promise of an unwavering commitment to patients that lies at the heart of everything we do.”

FineCross™ M3 combines Terumo’s legacy of engineering excellence with advanced design features tailored to address real-world challenges in PCI. Its 1.7 Fr tapered distal tip ensures superior lesion crossability, while a 15 cm floppy distal segment allows exceptional trackability through tortuous vessels. The tapered stainless-steel braided shaft enhances pushability and control, and the next-generation hydrophilic coating ensures outstanding lubrication and durability. Additionally, the PTFE inner layer with a radiopaque marker supports smooth device delivery and precise visualization during procedures.

Highlighting the product’s clinical relevance, Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India, noted, “FineCross™ M3 represents more than a product launch—it reinforces our continued focus on advancing cardiovascular care in India, in line with Terumo’s mission of contributing to society through healthcare. Through globally trusted innovations, we aim to empower physicians, deliver better patient outcomes, and create meaningful impact where it matters most.”

The launch of FineCross™ M3 further strengthens Terumo India’s expanding portfolio of interventional solutions and reaffirms its leadership in shaping the future of cardiovascular care in the country.